Human Epidermal Growth Factor Global Market Report 2025

The human epidermal growth factor market size has grown strongly in recent years. It will grow from $2.18 billion in 2024 to $2.39 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth during the historic period can be attributed to the expanding geriatric population susceptible to skin-related disorders, increased government support and funding for biopharmaceutical innovations, a rising prevalence of diabetes resulting in more chronic wound cases, enhanced collaborations between pharmaceutical companies and research institutes, and a growing consumer preference for non-invasive skincare solutions.

The human epidermal growth factor market size is expected to see strong growth in the next few years. It will grow to $3.37 billion in 2029 at a compound annual growth rate (CAGR) of 9%. The growth during the forecast period can be attributed to the rising demand for regenerative medicine and wound healing applications, increasing prevalence of chronic skin conditions and injuries, growing awareness of anti-aging and skincare products containing hEGF, expanding investment in biotechnology research and development, and the increasing adoption of personalized medicine and targeted therapies. Key trends in this period include advancements in recombinant DNA technology, developments in protein engineering that enhance hEGF stability and efficacy, integration of nanotechnology, innovations in bioprocessing techniques, and progress in cell culture technology.

The increasing adoption of personalized medicine is expected to drive the growth of the human epidermal growth factor market moving forward. Personalized medicine is a healthcare approach that customizes medical treatment based on an individual’s genetic profile, lifestyle, and environment to provide more precise and effective care. The rise in personalized medicine is fueled by advances in genomic technologies, which allow faster, more affordable, and more accurate identification of individual genetic profiles for tailored treatments. HER2 supports personalized medicine by enabling physicians to classify tumors according to HER2 protein overexpression, helping select targeted therapies that improve outcomes and minimize unnecessary side effects. For example, the Personalized Medicine Coalition, a US-based professional membership organization, reported that in 2022, 12 new personalized medicines were approved, representing about 34% of all newly approved therapies - a significant increase from previous years. Consequently, the growing use of personalized medicine is propelling the growth of the human epidermal growth factor market.

The rising number of clinical trials is expected to drive the growth of the human epidermal growth factor market in the future. Clinical trials are research studies involving human participants to assess the safety, effectiveness, and side effects of medical treatments or interventions. The increase in clinical trials is fueled by the growing demand for personalized and innovative therapies that require thorough testing for safety and efficacy. Human epidermal growth factor (hEGF) supports clinical trials by promoting cell growth and tissue repair, facilitating the evaluation of treatments for wound healing, skin regeneration, and related conditions. For example, in November 2023, the Association of the British Pharmaceutical Industry, a London-based trade association, reported a 15% increase in annual recruitment for industry clinical trials in the UK, rising from 36,722 participants in 2021-22 to 42,088 in 2022-23. Thus, the growth in clinical trials is propelling the expansion of the human epidermal growth factor market.

Leading companies in the human epidermal growth factor market are focusing on technological innovations such as AI-powered immunohistochemistry (IHC) scoring solutions to enhance the accuracy, speed, and consistency of biomarker detection and cancer diagnostics. An AI-powered IHC scoring solution uses artificial intelligence algorithms to automatically analyze and quantify protein expression in tissue samples stained via IHC, improving precision, reproducibility, and efficiency in diagnostic pathology. For example, in September 2023, Ibex Medical Analytics, an Israel-based company, introduced Ibex Breast HER2. This technology improves the precision and consistency of HER2 biomarker scoring in breast cancer, particularly in difficult HER2-low cases, enabling optimized treatment plans and better patient outcomes. Its key benefits include highly accurate, reproducible, and efficient HER2 IHC scoring, assisting pathologists in making confident, objective decisions for selecting targeted therapies.

Major players in the human epidermal growth factor market are Pfizer Inc., Johnson & Johnson Services Inc, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, AstraZeneca plc, Novartis AG, GlaxoSmithKline Plc, Amgen Inc., Lonza Group AG, STEMCELL Technologies, Abcam plc., BioLegend Inc., Bharat Biotech International Limited, RayBiotech Inc., Enzo Life Sciences Inc., Neocutis S.A, Proteintech Group Inc., Creative BioMart Co. Ltd., Abbkine Scientific Co. Ltd.

North America was the largest region in the human epidermal growth factor market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human epidermal growth factor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the human epidermal growth factor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Human epidermal growth factor (EGF) is a protein that promotes cell growth, proliferation, and differentiation by binding to the epidermal growth factor receptor (EGFR). It aids in accelerating wound healing by stimulating the migration and proliferation of skin cells like keratinocytes and fibroblasts, which are crucial for closing wounds and rebuilding tissue.

The main types of human epidermal growth factor products include recombinant human epidermal growth factor and natural human epidermal growth factor. Recombinant human epidermal growth factor (rhEGF) is a bioengineered protein created to stimulate cell growth and support tissue repair. It is available in various forms, such as injectable, topical, and oral. These products are distributed through multiple channels including direct sales, online pharmacies, retail pharmacies, hospital pharmacies, and specialty clinics. Key application areas cover dermatology, oncology, ophthalmology, wound healing, and cosmetic procedures. They are utilized by a range of end-users including hospitals, clinics, research institutes, and other healthcare facilities.

The human epidermal growth factor market research report is one of a series of new reports that provides human epidermal growth factor market statistics, including the human epidermal growth factor industry's global market size, regional shares, competitors with the human epidermal growth factor market share, detailed human epidermal growth factor market segments, market trends and opportunities, and any further data you may need to thrive in the human epidermal growth factor market. This human epidermal growth factor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The human epidermal growth factor market consists of sales of skincare serums and creams, wound-healing gels and ointments, and hair growth treatments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.